FIP Treatment Revolution and Access Equity

The transformation of FIP from 100% fatal to 85% treatable by GS-441524 represents one of veterinary medicine's greatest welfare advances, but access inequity remains a critical concern.

Key Facts

FIP was uniformly fatal for over 50 years with no effective treatment
GS-441524 achieves sustained remission in 85-90% of cats when treatment is completed
The 84-day minimum treatment course costs $3,000-8,000 in licensed markets
Unlicensed versions from overseas suppliers reduce cost but carry quality control concerns
Bova Compounding's licensed formulation has expanded access significantly in Australia

Welfare Considerations

The FIP treatment revolution is one of the most profound welfare advances in companion animal medicine - a previously untreatable, uniformly fatal disease now has a cure. However, access to this cure remains tragically inequitable. Cats owned by families who cannot afford licensed treatment still die from a curable disease. This welfare gap drives the use of unlicensed formulations of varying quality. Advocacy for affordable licensed access and veterinary charity support for treatment costs are direct welfare interventions.

What You Can Do

Contact the Bria Fund, Sock It To FIP, and other FIP assistance organizations if treatment cost is a barrier
Support campaigns for licensed affordable GS-441524 access in your country
Donate to FIP cat treatment assistance funds
Advocate for insurance coverage of FIP antiviral treatment